Brainstorm Cell Therapeutics (BCLI) Receives U.S. Patent Related to Mesenchymal Stem Cells Technology

October 31, 2016 7:01 AM EDT

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI) announced that it has been granted United States Patent No. 9,474,787 titled "Mesenchymal Stem Cells for the Treatment of CNS Diseases."

The allowed claims cover mesenchymal stem cells that secrete neurotrophic factors, including brain-derived neurotrophic factor (BDNF) and glial derived neurotrophic factor (GDNF), as well as a pharmaceutical compositions comprising these factors.

"We are pleased that the US Patent Office continues to recognize the innovative nature of NurOwn®, our proprietary, differentiated mesenchymal stem cells, for use as a pharmaceutical," commented BrainStorm's CEO Chaim Lebovits. "This patent, along with the previously granted patents and patent applications, is part of our strategy to aggressively establish a broad portfolio of intellectual property to protect all of our commercially important discoveries."

This patent is the result of Brainstorm's ongoing joint development of NurOwn® together with the Tel Aviv University, and reflects the collaboration between the company and the laboratory of Prof. Dani Offen, the company's chief scientist.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Litigation, Management Comments

Add Your Comment